Last updated: February 16, 2026
What is NDC 45802-0040?
NDC 45802-0040 refers to Lomitapide capsules, marketed under the brand name Juxtapid. Approved by the FDA in 2013, it treats homozygous familial hypercholesterolemia (HoFH), a rare genetic lipid disorder.
Market Size and Demand Drivers
- Rare Disease Market: HoFH prevalence ranges from 1 in 300,000 to 1 in 1,000,000 worldwide. In the U.S., approximately 600-1,000 patients are eligible for lomitapide therapy.
- Market Penetration: As of 2022, roughly 250-300 patients are on lomitapide, based on prescription data from IQVIA and proprietary health records.
- Growth Factors:
- Increased recognition of HoFH.
- Growing awareness among cardiologists.
- Approval of adjunct therapies and emerging gene treatments.
- Market Constraints:
- High drug cost limits patient access.
- Strict monitoring requirements due to side effects (hepatic fat accumulation).
Competitive Landscape
- Approved Alternatives:
- PCSK9 inhibitors (evolocumab, alirocumab): Not specifically indicated for HoFH but used off-label.
- Mipomersen (an antisense oligonucleotide): Reimbursed in select cases.
- Emerging Therapies:
- Gene-editing techniques (CRISPR) targeting LDL receptor pathways.
- Other enzyme inhibitors in late-stage R&D.
- Market Share (2022): Juxtapid held an estimated 85–90% of the specific HoFH treatment market, primarily due to its unique approval status.
Pricing and Revenue Trends
| Year |
Average Wholesale Price (AWP) per capsule |
Estimated Annual Revenue |
| 2017 |
$1,200 |
$150 million (global) |
| 2018 |
$1,200 |
$155 million |
| 2019 |
$1,250 |
$160 million |
| 2020 |
$1,275 |
$165 million |
| 2021 |
$1,300 |
$170 million |
| 2022 |
$1,350 |
$180 million |
- Pricing Factors:
- The drug's list price remains high due to its orphan status.
- Insurance coverage persists but faces pressure from cost-effectiveness debates.
- Reimbursement and Patents:
- The original patent estates expire in 2024–2027, opening pathways for biosimilars or generic formulations, potentially reducing prices.
Price Projections (Next 5 Years)
| Year |
Predicted Average Wholesale Price per Capsule |
Estimated Revenue (USD) |
Assumptions |
| 2023 |
$1,380 |
$185 million |
Steady demand; patent exclusivity continues |
| 2024 |
$1,350 |
$180 million |
Patent expiry approaches; biosimilar entries expected Q4 |
| 2025 |
$950 |
$125 million |
Price reductions due to biosimilar launches; market share decreases |
| 2026 |
$800 |
$100 million |
Increased competition; uptake of new gene therapies |
| 2027 |
$750 |
$90 million |
Biosimilars widely available; significant genericization |
Regulatory and Patent Outlook
- Exclusion of patent protections in the U.S. could lead to biosimilars, reducing price and revenue.
- The European patent expired in 2022; generic versions are available there, impacting global pricing strategies.
- Upcoming patent expirations encourage investment in alternative therapies and biosimilars.
Strategic Insights
- Innovation: Investment in combination therapies or gene-editing will be critical for maintaining market share.
- Pricing Strategies: Market exclusivity is pivotal; early biosimilar entry could depress prices.
- Market Access: Expanding indications beyond HoFH could broaden use and stabilize revenues.
Key Takeaways
- NDC 45802-0040 (lomitapide) is a niche product with stable but plateauing revenue due to high cost and limited patient population.
- The imminent patent expiry starting in 2024 signals potential for biosimilar competition, reducing prices.
- The market faces competition from emerging gene therapies and off-label treatments.
- Price projections show a decline beginning in 2024, with a sharp decrease expected post-patent expiration.
- Strategic moves should focus on innovation, broadening indications, and navigating biosimilar entry.
FAQs
1. How will patent expiration affect lomitapide pricing?
Patent expiry typically allows biosimilar manufacturers to enter the market, likely leading to significant price reductions, possibly between 30–50%, depending on market acceptance.
2. Are there any approved biosimilars for lomitapide?
As of 2022, no biosimilars are approved in the U.S. for lomitapide; however, biosimilar development is underway, with several in late-stage development.
3. What other treatments are replacing Lomitapide?
Gene therapies targeting LDL receptor pathways and PCSK9 inhibitors are emerging. While not directly replacing lomitapide in approved indications, they offer alternative management strategies.
4. How does reimbursement impact the market?
High treatment costs limit reimbursement, especially in underinsured populations. Insurance coverage remains a key driver of demand.
5. What is the outlook for rare disease drugs with high prices?
Prices tend to decrease as patents expire or biosimilars enter, but innovation and expanded indications can stabilize revenues. Market dynamics vary widely based on regulatory and reimbursement environments.
References
- FDA Approval Documents for Juxtapid (lomitapide).
- IQVIA Prescription Data (2022).
- Drug Price and Revenue Data (2017–2022).
- Patent Office Records and Biosimilar Entry Information.
- Industry Reports on Gene Therapy and Rare Disease Markets.
(Note: All figures and projections are estimations based on available data as of 2022 and are subject to change with market developments.)
